IL243941B - Polyconjugates for transporting rnai factors to cancer cells in vivo - Google Patents
Polyconjugates for transporting rnai factors to cancer cells in vivoInfo
- Publication number
- IL243941B IL243941B IL243941A IL24394116A IL243941B IL 243941 B IL243941 B IL 243941B IL 243941 A IL243941 A IL 243941A IL 24394116 A IL24394116 A IL 24394116A IL 243941 B IL243941 B IL 243941B
- Authority
- IL
- Israel
- Prior art keywords
- polyconjugates
- vivo
- delivery
- tumor cells
- rnai triggers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361863056P | 2013-08-07 | 2013-08-07 | |
| PCT/US2014/049851 WO2015021092A1 (en) | 2013-08-07 | 2014-08-06 | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| US14/452,626 US9487556B2 (en) | 2013-08-07 | 2014-08-06 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL243941A0 IL243941A0 (en) | 2016-04-21 |
| IL243941B true IL243941B (en) | 2019-06-30 |
Family
ID=52449177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243941A IL243941B (en) | 2013-08-07 | 2016-02-03 | Polyconjugates for transporting rnai factors to cancer cells in vivo |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9487556B2 (OSRAM) |
| EP (1) | EP3030244B1 (OSRAM) |
| JP (1) | JP6433001B2 (OSRAM) |
| KR (1) | KR20160035081A (OSRAM) |
| CN (1) | CN105451743B (OSRAM) |
| AU (1) | AU2014306021B2 (OSRAM) |
| CA (1) | CA2919088A1 (OSRAM) |
| EA (1) | EA201690051A1 (OSRAM) |
| IL (1) | IL243941B (OSRAM) |
| MX (1) | MX2016001006A (OSRAM) |
| SG (1) | SG11201600379TA (OSRAM) |
| TW (1) | TWI685347B (OSRAM) |
| WO (1) | WO2015021092A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201600379TA (en) * | 2013-08-07 | 2016-02-26 | Arrowhead Res Corp | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
| EP3271482A4 (en) | 2015-03-17 | 2019-02-13 | Arrowhead Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING THE GENE EXPRESSION OF FACTOR XII |
| CN107635550B (zh) * | 2015-03-17 | 2021-12-24 | 箭头药业股份有限公司 | 改良的含二硫化物的炔烃交联剂 |
| SG11201708602XA (en) | 2015-05-29 | 2017-12-28 | Arrowhead Pharmaceuticals Inc | Biologically cleavable tetrapeptide linking agents |
| BR112017025698A2 (pt) | 2015-05-29 | 2018-08-14 | Arrowhead Pharmaceuticals Inc | composições e métodos para inibir a expressão do gene de hif2alfa |
| EP3252082A1 (en) * | 2016-05-31 | 2017-12-06 | Galderma S.A. | Method for deacetylation of biopolymers |
| SI3397651T1 (sl) | 2015-12-29 | 2020-11-30 | Galderma S.A. | Oglikovodično zamreževalo |
| PT3623390T (pt) * | 2016-05-31 | 2023-10-27 | Galderma Sa | Reticulador de hidrato de carbono |
| US11629122B2 (en) | 2017-05-24 | 2023-04-18 | The Board Of Regents Of The University Of Texas System | Linkers for antibody drug conjugates |
| EP3784269B1 (en) | 2018-04-27 | 2024-06-05 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| MX2021008261A (es) | 2019-01-09 | 2021-08-16 | Arrowhead Pharmaceuticals Inc | Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso. |
| CN110240551B (zh) * | 2019-06-25 | 2022-02-11 | 成都郑源生化科技有限公司 | Fmoc-β-Ala-Gly-OH的制备方法 |
| TWI894184B (zh) | 2019-12-02 | 2025-08-21 | 瑞士商葛德瑪控股公司 | 高分子量美容組合物 |
| CN113004515B (zh) * | 2021-03-02 | 2023-02-24 | 厦门大学附属中山医院 | 一种仿透明质酸聚氨基酸衍生物、其制备方法及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO118290B1 (ro) * | 1995-08-30 | 2003-04-30 | Gdsearle & Co | Derivati de fenilcarboniluree si compozitie farmaceutica |
| PT889877E (pt) | 1996-03-29 | 2002-02-28 | Searle & Co | Derivados fenileno meta substituidos e sua utilizacao como antagonitas ou inibidores integrina alfa v beta3 |
| JP2001501600A (ja) * | 1996-09-10 | 2001-02-06 | ザ バーナム インスティテュート | 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法 |
| EP0870756B1 (fr) | 1997-04-07 | 2001-11-07 | Cfpi Nufarm | Procédé de préparation des dinitroanilines 3,4-disubstituées |
| JP5021152B2 (ja) * | 2001-10-22 | 2012-09-05 | ザ スクリプス リサーチ インスティチュート | インテグリンターゲッティング化合物 |
| JP2004261024A (ja) * | 2003-02-28 | 2004-09-24 | Japan Science & Technology Agency | ペプチド修飾多糖類を用いる遺伝子治療剤 |
| CA2488224A1 (en) * | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
| US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| CA2581869A1 (en) * | 2004-11-04 | 2006-05-18 | Raul Andino | Syntheses of polyamine conjugates of small interfering rnas (si-rnas) and conjugates formed thereby |
| CA2604441A1 (en) * | 2005-04-12 | 2006-10-19 | Intradigm Corporation | Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
| US8017109B2 (en) | 2006-08-18 | 2011-09-13 | Roche Madison Inc. | Endosomolytic poly(acrylate) polymers |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| AU2007296055A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| WO2008045252A2 (en) * | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US8513207B2 (en) | 2008-12-18 | 2013-08-20 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| NZ601737A (en) | 2010-02-24 | 2013-06-28 | Arrowhead Res Corp | Compositions for targeted delivery of sirna |
| US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| BR122020024394B1 (pt) * | 2010-12-29 | 2021-05-11 | F. Hoffmann-La Roche Ag | conjugado e composição farmacêutica |
| KR20130136494A (ko) * | 2010-12-29 | 2013-12-12 | 애로우헤드 리서치 코오포레이션 | 효소 민감성 결합을 갖는 Ｉｎ Ｖｉｖｏ 폴리뉴클레오티드 전달 컨쥬게이트 |
| JP2014531476A (ja) | 2011-08-26 | 2014-11-27 | アローヘッド リサーチ コーポレイション | インビボ核酸送達のためのポリ（ビニルエステル）ポリマー |
| BR112014016736A8 (pt) * | 2012-01-27 | 2017-07-04 | Hoffmann La Roche | composto, composição farmacêutica, método para tratamento, uso de um composto e invenção |
| CN104039356B (zh) | 2012-01-27 | 2018-08-17 | 弗·哈夫曼-拉罗切有限公司 | 用于靶向递送的、与小分子整联蛋白拮抗剂共价连接的壳聚糖 |
| CA2842041A1 (en) | 2012-04-18 | 2013-10-24 | Arrowhead Research Corporation | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| SG11201600379TA (en) * | 2013-08-07 | 2016-02-26 | Arrowhead Res Corp | Polyconjugates for delivery of rnai triggers to tumor cells in vivo |
-
2014
- 2014-08-06 SG SG11201600379TA patent/SG11201600379TA/en unknown
- 2014-08-06 JP JP2016533388A patent/JP6433001B2/ja active Active
- 2014-08-06 EA EA201690051A patent/EA201690051A1/ru unknown
- 2014-08-06 WO PCT/US2014/049851 patent/WO2015021092A1/en not_active Ceased
- 2014-08-06 US US14/452,626 patent/US9487556B2/en active Active
- 2014-08-06 MX MX2016001006A patent/MX2016001006A/es unknown
- 2014-08-06 EP EP14834389.0A patent/EP3030244B1/en active Active
- 2014-08-06 CN CN201480044362.9A patent/CN105451743B/zh active Active
- 2014-08-06 CA CA2919088A patent/CA2919088A1/en not_active Abandoned
- 2014-08-06 AU AU2014306021A patent/AU2014306021B2/en not_active Ceased
- 2014-08-06 KR KR1020167005887A patent/KR20160035081A/ko not_active Withdrawn
- 2014-08-07 TW TW103127144A patent/TWI685347B/zh not_active IP Right Cessation
-
2016
- 2016-02-03 IL IL243941A patent/IL243941B/en active IP Right Grant
- 2016-09-28 US US15/278,518 patent/US20170022497A1/en not_active Abandoned
-
2018
- 2018-11-13 US US16/189,550 patent/US20190062748A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015021092A1 (en) | 2015-02-12 |
| EA201690051A1 (ru) | 2016-06-30 |
| MX2016001006A (es) | 2016-04-19 |
| CN105451743A (zh) | 2016-03-30 |
| US9487556B2 (en) | 2016-11-08 |
| HK1220397A1 (zh) | 2017-05-05 |
| EP3030244A4 (en) | 2017-06-28 |
| EP3030244B1 (en) | 2021-04-21 |
| IL243941A0 (en) | 2016-04-21 |
| CN105451743B (zh) | 2019-11-19 |
| JP2016535058A (ja) | 2016-11-10 |
| SG11201600379TA (en) | 2016-02-26 |
| US20170022497A1 (en) | 2017-01-26 |
| US20190062748A1 (en) | 2019-02-28 |
| AU2014306021B2 (en) | 2018-12-13 |
| US20150045573A1 (en) | 2015-02-12 |
| EP3030244A1 (en) | 2016-06-15 |
| AU2014306021A2 (en) | 2016-11-24 |
| TWI685347B (zh) | 2020-02-21 |
| CA2919088A1 (en) | 2015-02-12 |
| AU2014306021A1 (en) | 2016-01-28 |
| KR20160035081A (ko) | 2016-03-30 |
| TW201601742A (zh) | 2016-01-16 |
| JP6433001B2 (ja) | 2018-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243941A0 (en) | Polyconjugates for transporting rnai factors to cancer cells in vivo | |
| IL244113B (en) | Selective delivery of substance to cells | |
| ZA201507790B (en) | Enhanced adoptive cell therapy | |
| PT2768493T (pt) | Fitocanabinoides para utilização no tratamento do cancro da mama | |
| PL3234107T3 (pl) | Limfocyty b do dostarczania in vivo środków terapeutycznych | |
| EP2971040A4 (en) | CELL CULTURE METHODS | |
| EP2971014A4 (en) | CELL CULTURE METHODS | |
| EP2919760A4 (en) | LIPOSOMES FOR IN VIVO RELEASE | |
| EP2872036A4 (en) | IN VIVO BIOSENSOR | |
| ZA201406726B (en) | Methods and composition related to brown adipose-like cells | |
| PL2925223T3 (pl) | Udoskonalone sposoby oceny funkcji metabolicznej | |
| SG11201405110TA (en) | Cell preparation including fat cell | |
| SG11201602060XA (en) | Improved methods of genetically modifying animal cells | |
| GB2510826B (en) | Improvements in or relating to release of a beneficial substance from a bolus | |
| ZA201408383B (en) | Improved endoglucanases for treatment of cellulosic material | |
| SG11201502214PA (en) | Adipose tissue cells | |
| GB201516123D0 (en) | In vivo cell imaging | |
| HUE039250T2 (hu) | A termék minõségének növelésére vonatkozó módszerek | |
| PL3082858T3 (pl) | Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu | |
| GB201302197D0 (en) | Method of increasing lipid accumulation in pulcherrima cells | |
| GB201304514D0 (en) | Cell delivery | |
| EP2738248A4 (en) | METHOD FOR THE PRODUCTION OF VITRO VASCULARIZED TISSUE | |
| EP2738249A4 (en) | METHOD FOR THE PRODUCTION OF VITRO VASCULARIZED TISSUE | |
| EP2720720A4 (en) | PLURITHERAPY TO PREVENT DCIS FORMATION AND EVOLUTION IN BREAST CANCER | |
| GB201216933D0 (en) | Adipose tissue cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |